TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02908256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geloplasma (PVI)
Description: In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geloplasma (delta PP)
Description: In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
Study: NCT01718561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SARI
Description: The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
Study: NCT04309942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Clinical Pharmacy Consultation
Description: These patients will have the benefit of a Guided Clinical Pharmacy Consultation
Study: NCT01159028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001
Description: Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 in combination with LDAC
Description: Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
Study: NCT03028870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V120083
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V120083
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen
Study: NCT02075099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tensing exercises
Description: Donors will do tensing exercises during blood donation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tensing exercises
Description: Donors will do tensing exercises during blood donation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tensing exercises
Description: Donors will do tensing exercises during blood donation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No tensing exercises
Description: Donors will not do tensing exercises during blood donation - control arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No tensing exercises
Description: Donors will not do tensing exercises during blood donation - control arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No tensing exercises
Description: Donors will not do tensing exercises during blood donation - control arm
Study: NCT01673711

Intervention type: DRUG
Intervention: deuterated phenanthrene tetraol
Description: Given PO

Intervention type: DRUG
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05193253

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
Study: NCT02411162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy GSK2894512 Cream A + GSK2894512 Cream B
Description: GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy Vehicle Cream A + Vehicle Cream B
Description: Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
Study: NCT04355741

Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.

Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.

Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
Study: NCT03955302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
Study: NCT02572674

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental follow up
Description: Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic sample
Description: Blood samples
Study: NCT00708123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: Fluoride free toothpaste (0 ppm F)
Study: NCT02676089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 200/6/12.5 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 200/6 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Study: NCT03235830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Standard of Care (ESoC) + Text
Description: See above in arm/group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care (ESoC)
Description: See above in arm/group description
Study: NCT01231594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other approved anti-cancer agent
Description: Study Drug
Study: NCT04041986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
Study: NCT03115736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
Study: NCT02354066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hallux valgus Shoe
Description: Brake response measurement after surgery with this foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hallux valgus Shoe
Description: Brake response measurement after surgery with this foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hallux valgus Shoe
Description: Brake response measurement after surgery with this foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forefoot relief shoe
Description: Brake response measurement after surgery with this foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forefoot relief shoe
Description: Brake response measurement after surgery with this foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forefoot relief shoe
Description: Brake response measurement after surgery with this foot orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retail Shoe
Description: Brake response time measurement before surgery (control run)
Study: NCT02374099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
Study: NCT03763071

Intervention type: OTHER
Intervention: Patient-reported scales to measure sleep disorders
Description: Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters
Study: NCT03022695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Study: NCT00262522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
Study: NCT00788372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
Study: NCT01315860

Intervention type: OTHER
Intervention: Postural Analysis
Description: Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
Study: NCT03349099

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook Flexor
Description: ureteral access sheath

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Navigator
Description: ureteral access sheath
Study: NCT01656148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Description: Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fampridine-SR
Description: Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
Study: NCT01053871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: conscious sedation using propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam with fentanyl
Description: conscious sedation using midazolam with fentanyl
Study: NCT00389792

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042
Description: no intervention

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042
Description: no intervention

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042
Description: no intervention

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042
Description: no intervention

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042 200 mg
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042 200 mg
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042 200 mg
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042 200 mg
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
Study: NCT03562572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemia driven revascularization
Description: In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
Study: NCT01805531

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
Study: NCT02639572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siloss® bone graft
Description: The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxyapatitie Bone graft
Description: The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
Study: NCT04523636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Pre-fabricated or custom resting hand splints

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Pre-fabricated or custom resting hand splints
Study: NCT01583933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essix retainer
Description: The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hawley retainer
Description: subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
Study: NCT03497481

Intervention type: BIOLOGICAL
Intervention: Samples
Description: Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
Study: NCT03181230

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02284789

Intervention type: OTHER
Group type: OTHER
Intervention: Colorado Adult Joint Assessment Evaluation
Description: Physical evaluation of 6 joints, ankles, knees and elbows
Study: NCT04202679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT04822051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Uncertainty Management Psychoeducation Program
Description: The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
Study: NCT02426021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202 Placebo
Description: Subcutaneous administration of MLN1202 placebo